Journal Article
. 2013 Mar; 19(5):1035-43.
doi: 10.1158/1078-0432.CCR-12-2064.

Agonistic CD40 antibodies and cancer therapy

Robert H Vonderheide 1 Martin J Glennie  
  • PMID: 23460534
  •     57 References
  •     201 citations


Recent success in cancer immunotherapy has reinvigorated the hypothesis that the immune system can control many if not most cancers, in some cases producing durable responses in a way not seen with many small-molecule drugs. Agonistic CD40 monoclonal antibodies (mAb) offer a new therapeutic option which has the potential to generate anticancer immunity by various mechanisms. CD40 is a TNF receptor superfamily member expressed broadly on antigen-presenting cells (APC) such as dendritic cells, B cells, and monocytes as well as many nonimmune cells and a range of tumors. Agonistic CD40 mAb have been shown to activate APC and promote antitumor T-cell responses and to foster cytotoxic myeloid cells with the potential to control cancer in the absence of T-cell immunity. Thus, agonistic CD40 mAb are fundamentally different from mAb which block negative immune checkpoint such as anti-CTLA-4 or anti-PD-1. Initial clinical trials of agonistic CD40 mAb have shown highly promising results in the absence of disabling toxicity, both in single-agent studies and in combination with chemotherapy; however, numerous questions remain about dose, schedule, route of administration, and formulation. Recent findings about the role played by the IgG isotype and the Fc gamma receptor (FcγR) in mAb cross-linking, together with insights into mechanisms of action, particularly with regard to the role of myeloid cells, are predicted to help design next-generation CD40 agonistic reagents with greater efficacy. Here, we will review the preclinical and clinical data and discuss the major issues facing the field.

Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin.
S Ghamande, B L Hylander, +3 authors, E A Repasky.
Cancer Res, 2001 Oct 19; 61(20). PMID: 11606394
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.
William Bensinger, Richard T Maziarz, +8 authors, Edward A Stadtmauer.
Br J Haematol, 2012 Aug 07; 159(1). PMID: 22861192
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.
Ann L White, H T Claude Chan, +10 authors, Martin J Glennie.
J Immunol, 2011 Jul 12; 187(4). PMID: 21742972
Agonist antibodies to TNFR molecules that costimulate T and NK cells.
Ignacio Melero, Daniel Hirschhorn-Cymerman, +2 authors, Jedd D Wolchok.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460535    Free PMC article.
Highly Cited.
Giving blood: a new role for CD40 in tumorigenesis.
Stephan Bergmann, Pier Paolo Pandolfi.
J Exp Med, 2006 Oct 18; 203(11). PMID: 17043147    Free PMC article.
CD40 and CD154 in cell-mediated immunity.
I S Grewal, R A Flavell.
Annu Rev Immunol, 1998 May 23; 16. PMID: 9597126
Highly Cited. Review.
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, +11 authors, IMPACT Study Investigators.
N Engl J Med, 2010 Sep 08; 363(5). PMID: 20818862
Highly Cited.
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.
Geertje J D van Mierlo, Annemieke Th den Boer, +5 authors, Rene E M Toes.
Proc Natl Acad Sci U S A, 2002 Apr 04; 99(8). PMID: 11929985    Free PMC article.
Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis.
A von Leoprechting, P van der Bruggen, +2 authors, J C Simon.
Cancer Res, 1999 Mar 30; 59(6). PMID: 10096561
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.
Richard R Furman, Andres Forero-Torres, Andrei Shustov, Jonathan G Drachman.
Leuk Lymphoma, 2009 Dec 30; 51(2). PMID: 20038235
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Gregory L Beatty, Elena G Chiorean, +10 authors, Robert H Vonderheide.
Science, 2011 Mar 26; 331(6024). PMID: 21436454    Free PMC article.
Highly Cited.
CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination.
R M Kedl, M Jordan, +3 authors, S Dow.
Proc Natl Acad Sci U S A, 2001 Aug 30; 98(19). PMID: 11526222    Free PMC article.
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.
Vanessa Berner, Haiyan Liu, +10 authors, William J Murphy.
Nat Med, 2007 Mar 06; 13(3). PMID: 17334371
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Inhibition of human B-cell lymphoma growth by CD40 stimulation.
S Funakoshi, D L Longo, +7 authors, W J Murphy.
Blood, 1994 May 15; 83(10). PMID: 7514045
In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Hillary D Lum, Ilia N Buhtoiarov, +4 authors, Alexander L Rakhmilevich.
J Leukoc Biol, 2006 Mar 28; 79(6). PMID: 16565324
Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.
Ignacio Melero, Antonio M Grimaldi, Jose L Perez-Gracia, Paolo A Ascierto.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460531
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Immunostimulatory monoclonal antibodies for cancer therapy.
Ignacio Melero, Sandra Hervas-Stubbs, +2 authors, Lieping Chen.
Nat Rev Cancer, 2007 Jan 26; 7(2). PMID: 17251916
Highly Cited. Review.
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.
Robert H Vonderheide, Jennifer M Burg, +5 authors, Omid Hamid.
Oncoimmunology, 2013 Mar 14; 2(1). PMID: 23483678    Free PMC article.
T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.
Alison L Tutt, Lyn O'Brien, +3 authors, Martin J Glennie.
J Immunol, 2002 Mar 09; 168(6). PMID: 11884438
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma.
Mohamad Hussein, James R Berenson, +6 authors, Nancy Whiting.
Haematologica, 2010 Feb 06; 95(5). PMID: 20133895    Free PMC article.
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.
Jens Rüter, Scott J Antonia, +2 authors, Robert H Vonderheide.
Cancer Biol Ther, 2010 Sep 22; 10(10). PMID: 20855968    Free PMC article.
CD40-CD40 ligand.
C van Kooten, J Banchereau.
J Leukoc Biol, 2000 Jan 27; 67(1). PMID: 10647992
Highly Cited. Review.
Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Marieke F Fransen, Marjolein Sluijter, +2 authors, Cornelis J M Melief.
Clin Cancer Res, 2011 Mar 11; 17(8). PMID: 21389097
Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia.
Arman Hasani, Kynan Feeney, Anna Nowak, Michael Millward.
Asia Pac J Clin Oncol, 2010 Dec 01; 6(4). PMID: 21114785
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893.
Anusha Kalbasi, Ester Fonsatti, +9 authors, Antoni Ribas.
J Immunother, 2010 Sep 16; 33(8). PMID: 20842056
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
J L Schultze, S Michalak, +6 authors, L M Nadler.
J Clin Invest, 1998 Feb 12; 100(11). PMID: 9389740    Free PMC article.
Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production.
Ewen Gallagher, Thomas Enzler, +6 authors, Michael Karin.
Nat Immunol, 2006 Dec 05; 8(1). PMID: 17143273
The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.
Ronald P Gladue, Timothy Paradis, +8 authors, Vahe Bedian.
Cancer Immunol Immunother, 2011 Apr 12; 60(7). PMID: 21479995
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Ranjana Advani, Andres Forero-Torres, +6 authors, Jonathan G Drachman.
J Clin Oncol, 2009 Jul 29; 27(26). PMID: 19636010
The role of the CD40 pathway in the pathogenesis and treatment of cancer.
Aristides G Eliopoulos, Lawrence S Young.
Curr Opin Pharmacol, 2004 Jul 15; 4(4). PMID: 15251129
Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Sapna Khubchandani, Myron S Czuczman, Francisco J Hernandez-Ilizaliturri.
Curr Opin Investig Drugs, 2009 Jun 11; 10(6). PMID: 19513947
The application of monoclonal antibodies in the treatment of lymphoma.
M J Glennie, J Honeychurch, R R French, A L Tutt.
Methods Mol Med, 2000 Jan 01; 40. PMID: 21337085
Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.
Brent A Hanks, Jianghong Jiang, +5 authors, David M Spencer.
Nat Med, 2005 Jan 25; 11(2). PMID: 15665830
Triggering CD40 on endothelial cells contributes to tumor growth.
Claudia Chiodoni, Manuela Iezzi, +7 authors, Mario P Colombo.
J Exp Med, 2006 Oct 18; 203(11). PMID: 17043144    Free PMC article.
Phase I study of recombinant human CD40 ligand in cancer patients.
R H Vonderheide, J P Dutcher, +10 authors, J G Gribben.
J Clin Oncol, 2001 Jul 04; 19(13). PMID: 11432896
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.
Mario Sznol, Lieping Chen.
Clin Cancer Res, 2013 Sep 21; 19(19). PMID: 24048329    Free PMC article.
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
Robert H Vonderheide, Keith T Flaherty, +12 authors, Scott J Antonia.
J Clin Oncol, 2007 Mar 01; 25(7). PMID: 17327609
Highly Cited.
Prospect of targeting the CD40 pathway for cancer therapy.
Robert H Vonderheide.
Clin Cancer Res, 2007 Feb 24; 13(4). PMID: 17317815
CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily.
A G Eliopoulos, C Davies, +4 authors, L S Young.
Mol Cell Biol, 2000 Jul 13; 20(15). PMID: 10891490    Free PMC article.
Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes.
Hajir Dadgostar, Brian Zarnegar, +5 authors, Genhong Cheng.
Proc Natl Acad Sci U S A, 2002 Feb 07; 99(3). PMID: 11830667    Free PMC article.
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Fubin Li, Jeffrey V Ravetch.
Science, 2011 Aug 20; 333(6045). PMID: 21852502    Free PMC article.
Highly Cited.
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.
Paolo A Ascierto, Michael Kalos, +2 authors, Jedd D Wolchok.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460532
Highly Cited.
FcgammaRIV: a novel FcR with distinct IgG subclass specificity.
Falk Nimmerjahn, Pierre Bruhns, Ken Horiuchi, Jeffrey V Ravetch.
Immunity, 2005 Jul 26; 23(1). PMID: 16039578
Highly Cited.
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex.
Atsushi Matsuzawa, Ping-Hui Tseng, +6 authors, Michael Karin.
Science, 2008 Jul 19; 321(5889). PMID: 18635759    Free PMC article.
Highly Cited.
Prospects for CD40-directed experimental therapy of human cancer.
Alex W Tong, Marvin J Stone.
Cancer Gene Ther, 2002 Dec 19; 10(1). PMID: 12489023
Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Timothy S Lewis, Renee S McCormick, +5 authors, Che-Leung Law.
Clin Cancer Res, 2011 May 26; 17(14). PMID: 21610152
CD40 ligation for immunotherapy of solid tumours.
S M Todryk, A L Tutt, +4 authors, M J Glennie.
J Immunol Methods, 2001 Feb 27; 248(1-2). PMID: 11223075
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.
Bart Burington, Peng Yue, +26 authors, David Dornan.
Sci Transl Med, 2011 Mar 18; 3(74). PMID: 21411738
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.
R R French, H T Chan, A L Tutt, M J Glennie.
Nat Med, 1999 May 06; 5(5). PMID: 10229232
Highly Cited.
Use of oligonucleotide aptamer ligands to modulate the function of immune receptors.
Eli Gilboa, James McNamara, Fernando Pastor.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460536
RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
N J Mason, C M Coughlin, +7 authors, R H Vonderheide.
Gene Ther, 2008 Mar 14; 15(13). PMID: 18337841
Mouse model recapitulating human Fcγ receptor structural and functional diversity.
Patrick Smith, David J DiLillo, +2 authors, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2012 Apr 05; 109(16). PMID: 22474370    Free PMC article.
Highly Cited.
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.
Pierre Bruhns, Bruno Iannascoli, +4 authors, Marc Daëron.
Blood, 2008 Nov 20; 113(16). PMID: 19018092
Highly Cited.
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.
Andres Forero-Torres, Nancy Bartlett, +7 authors, Craig H Moskowitz.
Leuk Lymphoma, 2012 Jul 11; 54(2). PMID: 22775314
Inflammatory networks and immune surveillance of pancreatic carcinoma.
Robert H Vonderheide, Lauren J Bayne.
Curr Opin Immunol, 2013 Feb 21; 25(2). PMID: 23422836    Free PMC article.
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Mario Sznol, Lieping Chen.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460533    Free PMC article.
Highly Cited.
Agonist antibodies to TNFR molecules that costimulate T and NK cells.
Ignacio Melero, Daniel Hirschhorn-Cymerman, +2 authors, Jedd D Wolchok.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460535    Free PMC article.
Highly Cited.
CD40 immunotherapy for pancreatic cancer.
Robert H Vonderheide, David L Bajor, +3 authors, Gregory L Beatty.
Cancer Immunol Immunother, 2013 Apr 17; 62(5). PMID: 23589109    Free PMC article.
Evolving pharmacotherapies for the treatment of metastatic melanoma.
April K S Salama.
Clin Med Insights Oncol, 2013 Jul 12; 7. PMID: 23843723    Free PMC article.
CD40 therapy and surgery: a potential immunologic partnership.
Katelyn T Byrne, Robert H Vonderheide.
J Immunother, 2013 Aug 09; 36(7). PMID: 23924786    Free PMC article.
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.
Ryan J Sullivan, Patricia M Lorusso, Keith T Flaherty.
Clin Cancer Res, 2013 Oct 04; 19(19). PMID: 24089441    Free PMC article.
Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics.
Sachin Gupta, James M Termini, Saravana Kanagavelu, Geoffrey W Stone.
Immunol Res, 2013 Nov 08; 57(1-3). PMID: 24198065    Free PMC article.
Microenvironmental regulation of tumor progression and metastasis.
Daniela F Quail, Johanna A Joyce.
Nat Med, 2013 Nov 10; 19(11). PMID: 24202395    Free PMC article.
Highly Cited. Review.
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.
Julie E Bauman, Robert L Ferris.
Cancer, 2013 Nov 14; 120(5). PMID: 24222079    Free PMC article.
CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells.
M El-Mesery, J Trebing, +3 authors, H Wajant.
Cell Death Dis, 2013 Nov 16; 4. PMID: 24232092    Free PMC article.
Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Lee P Richman, Robert H Vonderheide.
Cancer Immunol Res, 2014 Jan 15; 2(1). PMID: 24416732    Free PMC article.
Mitigating the toxic effects of anticancer immunotherapy.
Tara C Gangadhar, Robert H Vonderheide.
Nat Rev Clin Oncol, 2014 Jan 22; 11(2). PMID: 24445516
Highly Cited. Review.
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
Darshil J Shah, Roxana S Dronca.
Mayo Clin Proc, 2014 Apr 02; 89(4). PMID: 24684873    Free PMC article.
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.
Ping-Chih Ho, Katrina M Meeth, +3 authors, Susan M Kaech.
Cancer Res, 2014 Apr 17; 74(12). PMID: 24736544    Free PMC article.
CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.
Jonathan M Weiss, W Gregory Alvord, +2 authors, Robert H Wiltrout.
Hum Immunol, 2014 May 08; 75(7). PMID: 24801648    Free PMC article.
B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer.
Anastasia Meshcheryakova, Dietmar Tamandl, +9 authors, Diana Mechtcheriakova.
PLoS One, 2014 Jun 07; 9(6). PMID: 24905750    Free PMC article.
Dendritic cell-targeted vaccines.
Lillian Cohn, Lélia Delamarre.
Front Immunol, 2014 Jun 10; 5. PMID: 24910635    Free PMC article.
Highly Cited. Review.
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
Sven de Vos, Andres Forero-Torres, +10 authors, Ranjana Advani.
J Hematol Oncol, 2014 Jun 13; 7. PMID: 24919462    Free PMC article.
Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models.
Kouichi Furugaki, Lin Cui, +5 authors, Kenji Nakano.
PLoS One, 2014 Jul 12; 9(7). PMID: 25013909    Free PMC article.
Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression.
Mark J Smyth, Michele W L Teng.
Oncoimmunology, 2014 Aug 02; 3. PMID: 25083324    Free PMC article.
Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking.
Lee P Richman, Robert H Vonderheide.
Oncoimmunology, 2014 Aug 07; 3. PMID: 25097801    Free PMC article.
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.
David L Bajor, Xiaowei Xu, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2014 Sep 26; 2(11). PMID: 25252722    Free PMC article.
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.
Ann L White, H T Claude Chan, +15 authors, Martin J Glennie.
Cancer Cell, 2014 Dec 17; 27(1). PMID: 25500122    Free PMC article.
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies.
Jing Liu, Stephen J Blake, Mark J Smyth, Michele Wl Teng.
Clin Transl Immunology, 2014 Dec 17; 3(8). PMID: 25505970    Free PMC article.
Are macrophages in tumors good targets for novel therapeutic approaches?
Samthosh V Alahari, Shengli Dong, Suresh K Alahari.
Mol Cells, 2014 Dec 19; 38(2). PMID: 25518927    Free PMC article.
Microenvironmental regulation of therapeutic response in cancer.
Florian Klemm, Johanna A Joyce.
Trends Cell Biol, 2014 Dec 30; 25(4). PMID: 25540894    Free PMC article.
Highly Cited. Review.
Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.
Kevin J Curran, Beatrijs A Seinstra, +6 authors, Renier J Brentjens.
Mol Ther, 2015 Jan 15; 23(4). PMID: 25582824    Free PMC article.
Highly Cited.
Multifaceted antitumor responses to activating anti-CD40 antibody therapy combined with immunomodulatory or targeted agents.
Jonathan M Weiss, Robert H Wiltout.
Oncoimmunology, 2015 Jan 23; 3(8). PMID: 25610748    Free PMC article.
Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.
José Medina-Echeverz, Chi Ma, +5 authors, Tim F Greten.
Cancer Immunol Res, 2015 Feb 01; 3(5). PMID: 25637366    Free PMC article.
Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma.
Yong Zhang, Xiaoyan Hu, +7 authors, Li Liu.
J Exp Clin Cancer Res, 2015 Feb 06; 34. PMID: 25651850    Free PMC article.
Targeting the tumor microenvironment to enhance antitumor immune responses.
Kevin Van der Jeught, Lukasz Bialkowski, +7 authors, Karine Breckpot.
Oncotarget, 2015 Feb 16; 6(3). PMID: 25682197    Free PMC article.
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges.
Maria Vela, Mariana Aris, +2 authors, Leonor Kremer.
Front Immunol, 2015 Feb 18; 6. PMID: 25688243    Free PMC article.
Highly Cited. Review.
Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.
Jeffrey Lee Jensen, Alexander Rakhmilevich, +11 authors, Fotis Asimakopoulos.
Cancer Immunol Res, 2015 May 06; 3(8). PMID: 25941352    Free PMC article.
Development of individualized anti-metastasis strategies by engineering nanomedicines.
Qianjun He, Shengrong Guo, Zhiyong Qian, Xiaoyuan Chen.
Chem Soc Rev, 2015 Jun 10; 44(17). PMID: 26056688    Free PMC article.
Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.
Elizabeth A Thompson, Frank Liang, +7 authors, Karin Loré.
J Immunol, 2015 Jul 01; 195(3). PMID: 26123354    Free PMC article.
Kick-starting the cancer-immunity cycle by targeting CD40.
P Ellmark, S M Mangsbo, +2 authors, P Norlén.
Oncoimmunology, 2015 Jul 04; 4(7). PMID: 26140231    Free PMC article.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Ignacio Melero, David M Berman, +3 authors, John Haanen.
Nat Rev Cancer, 2015 Jul 25; 15(8). PMID: 26205340
Highly Cited. Review.
Therapeutic cancer vaccines.
Cornelis J M Melief, Thorbald van Hall, +2 authors, Sjoerd H van der Burg.
J Clin Invest, 2015 Jul 28; 125(9). PMID: 26214521    Free PMC article.
Highly Cited. Review.
Antibody-based immunotherapy of solid cancers: progress and possibilities.
Christopher F Nicodemus.
Immunotherapy, 2015 Sep 01; 7(8). PMID: 26314410    Free PMC article.
Immunotherapy and tumor microenvironment.
Haidong Tang, Jian Qiao, Yang-Xin Fu.
Cancer Lett, 2015 Oct 20; 370(1). PMID: 26477683    Free PMC article.
Highly Cited. Review.
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab.
Venky Ramakrishna, Karuna Sundarapandiyan, +3 authors, Tibor Keler.
J Immunother Cancer, 2015 Oct 27; 3. PMID: 26500773    Free PMC article.
Melanoma: oncogenic drivers and the immune system.
Niki Karachaliou, Sara Pilotto, +10 authors, Rafael Rosell.
Ann Transl Med, 2015 Nov 26; 3(18). PMID: 26605311    Free PMC article.
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.
Julie Jacobs, Evelien Smits, +2 authors, Vanessa Deschoolmeester.
J Immunol Res, 2015 Nov 26; 2015. PMID: 26605342    Free PMC article.
In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.
Linda Hammerich, Adam Binder, Joshua D Brody.
Mol Oncol, 2015 Dec 04; 9(10). PMID: 26632446    Free PMC article.
Macrophages and pancreatic ductal adenocarcinoma.
Aida Habtezion, Mouad Edderkaoui, Stephen J Pandol.
Cancer Lett, 2015 Dec 29; 381(1). PMID: 26708507    Free PMC article.
Tumour progression and metastasis.
Francisco Arvelo, Felipe Sojo, Carlos Cotte.
Ecancermedicalscience, 2016 Feb 26; 10. PMID: 26913068    Free PMC article.
Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
Takuhiro Shoji, Ryuta Saito, +7 authors, Teiji Tominaga.
Neuro Oncol, 2016 Feb 27; 18(8). PMID: 26917236    Free PMC article.
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
Nadia M Luheshi, Jane Coates-Ulrichsen, +8 authors, Robert W Wilkinson.
Oncotarget, 2016 Feb 27; 7(14). PMID: 26918344    Free PMC article.
Deploying myeloid cells against myeloma.
Jeffrey L Jensen, Chelsea Hope, Fotis Asimakopoulos.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141348    Free PMC article.
CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
Katelyn T Byrne, Nathan H Leisenring, David L Bajor, Robert H Vonderheide.
J Immunol, 2016 May 25; 197(1). PMID: 27217585    Free PMC article.
Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.
Simon J Dovedi, Grazyna Lipowska-Bhalla, +5 authors, Jamie Honeychurch.
Cancer Immunol Res, 2016 Jun 01; 4(7). PMID: 27241845    Free PMC article.
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Rony Dahan, Bryan C Barnhart, +3 authors, Jeffrey V Ravetch.
Cancer Cell, 2016 Jun 07; 29(6). PMID: 27265505    Free PMC article.
Highly Cited.
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Katelyn T Byrne, Robert H Vonderheide.
Cell Rep, 2016 Jun 14; 15(12). PMID: 27292635    Free PMC article.
Highly Cited.
Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity.
Caroline Baer, Mario Leonardo Squadrito, +7 authors, Michele De Palma.
Nat Cell Biol, 2016 Jun 14; 18(7). PMID: 27295554
Highly Cited.
A current perspective on applications of macrocyclic-peptide-based high-affinity ligands.
Daniël Leenheer, Peter Ten Dijke, Christopher John Hipolito.
Biopolymers, 2016 Jun 30; 106(6). PMID: 27352774    Free PMC article.
Neoadjuvant therapy for pancreatic cancer: an ongoing debate.
Suzanne Russo, M Wasif Saif.
Therap Adv Gastroenterol, 2016 Jul 02; 9(4). PMID: 27366211    Free PMC article.
Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
Guoqi Song, Huiyun Ni, +4 authors, William C Cho.
Onco Targets Ther, 2016 Jul 07; 9. PMID: 27382316    Free PMC article.
Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
Luuk van Hooren, Maria Georganaki, +2 authors, Anna Dimberg.
Oncotarget, 2016 Jul 08; 7(31). PMID: 27385210    Free PMC article.
Regulatory circuits of T cell function in cancer.
Daniel E Speiser, Ping-Chih Ho, Grégory Verdeil.
Nat Rev Immunol, 2016 Aug 17; 16(10). PMID: 27526640
Highly Cited. Review.
Targeting CD73 in the tumor microenvironment with MEDI9447.
Carl M Hay, Erin Sult, +15 authors, Kris F Sachsenmeier.
Oncoimmunology, 2016 Sep 14; 5(8). PMID: 27622077    Free PMC article.
Highly Cited.
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination.
Anke Redeker, Ramon Arens.
Front Immunol, 2016 Sep 23; 7. PMID: 27656185    Free PMC article.
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.
Peter Ellmark, Sara M Mangsbo, +2 authors, Thomas H Tötterman.
Cancer Immunol Immunother, 2016 Oct 08; 66(1). PMID: 27714433    Free PMC article.
AFM study shows prominent physical changes in elasticity and pericellular layer in human acute leukemic cells due to inadequate cell-cell communication.
Nataliia V Guz, Sapan J Patel, +2 authors, Igor Sokolov.
Nanotechnology, 2016 Nov 12; 27(49). PMID: 27834315    Free PMC article.
Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.
B Bonavida, S Chouaib.
Ann Oncol, 2016 Nov 20; 28(3). PMID: 27864216    Free PMC article.
Enhancing radiotherapy for lung cancer using immunoadjuvants delivered in situ from new design radiotherapy biomaterials: a preclinical study.
Yao Hao, Sayeda Yasmin-Karim, +3 authors, Wilfred Ngwa.
Phys Med Biol, 2016 Dec 03; 61(24). PMID: 27910826    Free PMC article.
Targeting cancer-related inflammation in the era of immunotherapy.
Kyohei Nakamura, Mark J Smyth.
Immunol Cell Biol, 2016 Dec 22; 95(4). PMID: 27999432
Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy.
Kristin L Griffiths, Mushtaq Ahmed, +9 authors, Shabaana A Khader.
Nat Commun, 2016 Dec 23; 7. PMID: 28004802    Free PMC article.
Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins.
Juliane Kums, Johannes Nelke, +3 authors, Harald Wajant.
MAbs, 2017 Jan 18; 9(3). PMID: 28095113    Free PMC article.
Differentiated State of Initiating Tumor Cells Is Key to Distinctive Immune Responses Seen in H-RasG12V-Induced Squamous Tumors.
Michael A Podolsky, Jacob T Bailey, +3 authors, Adam B Glick.
Cancer Immunol Res, 2017 Feb 01; 5(3). PMID: 28137717    Free PMC article.
Aptamers for CD Antigens: From Cell Profiling to Activity Modulation.
Amin Nozari, Maxim V Berezovski.
Mol Ther Nucleic Acids, 2017 Mar 23; 6. PMID: 28325295    Free PMC article.
Progress in tumor-associated macrophage (TAM)-targeted therapeutics.
Chayanon Ngambenjawong, Heather H Gustafson, Suzie H Pun.
Adv Drug Deliv Rev, 2017 Apr 30; 114. PMID: 28449873    Free PMC article.
Highly Cited. Review.
Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
Jessica M Moskovitz, Jennifer Moy, Tanguy Y Seiwert, Robert L Ferris.
Oncologist, 2017 May 17; 22(6). PMID: 28507203    Free PMC article.
Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters.
Alison M McDonnell, Alistair Cook, +2 authors, Anna K Nowak.
BMC Cancer, 2017 Jun 18; 17(1). PMID: 28619093    Free PMC article.
Tumor-Associated Macrophages as Target for Antitumor Therapy.
Katarzyna Sawa-Wejksza, Martyna Kandefer-Szerszeń.
Arch Immunol Ther Exp (Warsz), 2017 Jul 01; 66(2). PMID: 28660349    Free PMC article.
Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation.
Jin Dai, Pu Fang, +8 authors, Hong Wang.
J Hematol Oncol, 2017 Jul 26; 10(1). PMID: 28738836    Free PMC article.
CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
Anna Wasiuk, James Testa, +9 authors, Li-Zhen He.
J Immunol, 2017 Nov 08; 199(12). PMID: 29109120    Free PMC article.
Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Fredrik N Albach, Frank Wagner, +6 authors, Jürgen Steffgen.
Eur J Clin Pharmacol, 2017 Nov 12; 74(2). PMID: 29127458    Free PMC article.
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.
Manisha Singh, Christina Vianden, +15 authors, Willem W Overwijk.
Nat Commun, 2017 Nov 14; 8(1). PMID: 29129918    Free PMC article.
Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
Paul J Carter, Greg A Lazar.
Nat Rev Drug Discov, 2017 Dec 02; 17(3). PMID: 29192287
Highly Cited. Review.
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Mariona Cabo, Rienk Offringa, +3 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Dec 07; 6(12). PMID: 29209572    Free PMC article.
Towards personalized, tumour-specific, therapeutic vaccines for cancer.
Zhuting Hu, Patrick A Ott, Catherine J Wu.
Nat Rev Immunol, 2017 Dec 12; 18(3). PMID: 29226910    Free PMC article.
Highly Cited. Review.
Emerging trends in the immunotherapy of pancreatic cancer.
Kasturi Banerjee, Sushil Kumar, +10 authors, Maneesh Jain.
Cancer Lett, 2017 Dec 16; 417. PMID: 29242097    Free PMC article.
Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity.
Yuan Zhang, Na Li, Heikyung Suh, Darrell J Irvine.
Nat Commun, 2018 Jan 04; 9(1). PMID: 29295974    Free PMC article.
Highly Cited.
Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors.
Lindsay K Ward-Kavanagh, Kathleen M Kokolus, +2 authors, Todd D Schell.
Cancer Immunol Immunother, 2018 Jan 15; 67(4). PMID: 29332158    Free PMC article.
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.
Sabine Hoves, Chia-Huey Ooi, +15 authors, Carola H Ries.
J Exp Med, 2018 Feb 14; 215(3). PMID: 29436396    Free PMC article.
Highly Cited.
Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors.
Jennifer Q Zhang, Shan Zeng, +13 authors, Ronald P DeMatteo.
Cancer Immunol Res, 2018 Feb 23; 6(4). PMID: 29467128    Free PMC article.
Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Julian A Marin-Acevedo, Bhagirathbhai Dholaria, +3 authors, Yanyan Lou.
J Hematol Oncol, 2018 Mar 17; 11(1). PMID: 29544515    Free PMC article.
Highly Cited. Review.
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Xiaojie Yu, H T Claude Chan, +14 authors, Ann L White.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576376    Free PMC article.
The Immune Revolution: A Case for Priming, Not Checkpoint.
Robert H Vonderheide.
Cancer Cell, 2018 Apr 11; 33(4). PMID: 29634944    Free PMC article.
Highly Cited. Review.
Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.
Damir Bojadzic, Peter Buchwald.
Curr Top Med Chem, 2018 Jun 01; 18(8). PMID: 29848279    Free PMC article.
Immunotherapy and Prevention of Pancreatic Cancer.
Alexander H Morrison, Katelyn T Byrne, Robert H Vonderheide.
Trends Cancer, 2018 Jun 05; 4(6). PMID: 29860986    Free PMC article.
Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Jeremy D Waight, Dhan Chand, +14 authors, Nicholas S Wilson.
Cancer Cell, 2018 Jun 13; 33(6). PMID: 29894690    Free PMC article.
The promise and challenges of immune agonist antibody development in cancer.
Patrick A Mayes, Kenneth W Hance, Axel Hoos.
Nat Rev Drug Discov, 2018 Jun 16; 17(7). PMID: 29904196
Highly Cited. Review.
Next generation immune-checkpoints for cancer therapy.
Chiara Donini, Lorenzo D'Ambrosio, +2 authors, Dario Sangiolo.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951308    Free PMC article.
Bispecific antibodies in cancer immunotherapy.
Eva Dahlén, Niina Veitonmäki, Per Norlén.
Ther Adv Vaccines Immunother, 2018 Jul 13; 6(1). PMID: 29998217    Free PMC article.
Highly Cited. Review.
Emerging strategies for combination checkpoint modulators in cancer immunotherapy.
Aleksandra Popovic, Elizabeth M Jaffee, Neeha Zaidi.
J Clin Invest, 2018 Aug 02; 128(8). PMID: 30067248    Free PMC article.
Highly Cited. Review.
Oncolytic virus and PD-1/PD-L1 blockade combination therapy.
Chun-Yu Chen, Brian Hutzen, Mary F Wedekind, Timothy P Cripe.
Oncolytic Virother, 2018 Aug 15; 7. PMID: 30105219    Free PMC article.
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors.
Yang Liu, Yinping Dong, +3 authors, Jinming Yu.
J Hematol Oncol, 2018 Aug 18; 11(1). PMID: 30115069    Free PMC article.
Highly Cited. Review.
Personalized cancer neoantigen vaccines come of age.
Yanhong Chu, Qin Liu, Jia Wei, Baorui Liu.
Theranostics, 2018 Aug 22; 8(15). PMID: 30128050    Free PMC article.
Immunotherapy of hepatocellular carcinoma.
Bruno Sangro, Daniel Palmer, Ignacio Melero.
Hepat Oncol, 2014 Oct 01; 1(4). PMID: 30190978    Free PMC article.
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.
David L Bajor, Rosemarie Mick, +15 authors, Robert H Vonderheide.
Oncoimmunology, 2018 Oct 06; 7(10). PMID: 30288340    Free PMC article.
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
David A Knorr, Rony Dahan, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2018 Oct 10; 115(43). PMID: 30297432    Free PMC article.
Immune regulation of metastasis: mechanistic insights and therapeutic opportunities.
Olga S Blomberg, Lorenzo Spagnuolo, Karin E de Visser.
Dis Model Mech, 2018 Oct 26; 11(10). PMID: 30355585    Free PMC article.
Efficacy of different hemodialysis methods on dendritic cell marker CD40 and CD80 and platelet activation marker CD62P and P10 in patients with chronic renal failure.
Xin-Fang Wang, Bei-Hao Zhang, Xiao-Qing Lu, Pei Wang.
J Clin Lab Anal, 2018 Dec 01; 33(3). PMID: 30499177    Free PMC article.
Considerations for the Design of Antibody-Based Therapeutics.
Dennis R Goulet, William M Atkins.
J Pharm Sci, 2019 Jun 08; 109(1). PMID: 31173761    Free PMC article.
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
José Medina-Echeverz, Maria Hinterberger, +11 authors, Henning Lauterbach.
Nat Commun, 2019 Nov 07; 10(1). PMID: 31695037    Free PMC article.
Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy.
Jia Zhuang, Maya Holay, +3 authors, Liangfang Zhang.
Theranostics, 2019 Nov 07; 9(25). PMID: 31695803    Free PMC article.
Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.
Ondrej Uher, Veronika Caisova, +5 authors, Karel Pacak.
Semin Oncol, 2019 Nov 20; 46(4-5). PMID: 31739997    Free PMC article.
Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells.
Jihyun Lim, Aram Lee, Hee Gu Lee, Jong-Seok Lim.
Biomol Ther (Seoul), 2019 Aug 23; 28(1). PMID: 31431006    Free PMC article.
TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Alisha Holtzhausen, William Harris, +9 authors, H Shelton Earp.
Cancer Immunol Res, 2019 Aug 28; 7(10). PMID: 31451482    Free PMC article.
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
Kyohei Nakamura, Mark J Smyth.
Cell Mol Immunol, 2019 Oct 16; 17(1). PMID: 31611651    Free PMC article.
Highly Cited. Review.
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Abhishek S Kashyap, Martina Schmittnaegel, +18 authors, Alfred Zippelius.
Proc Natl Acad Sci U S A, 2020 Jan 01; 117(1). PMID: 31889004    Free PMC article.
Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response.
Laura Lorenzo-Sanz, Purificación Muñoz.
Cancer Microenviron, 2019 Oct 05; 12(2-3). PMID: 31583529    Free PMC article.
Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers.
Yang Ge, C Benedikt Westphalen, +2 authors, Nathaniel Weygant.
J Oncol, 2020 Feb 23; 2019. PMID: 32082375    Free PMC article.
The making and function of CAR cells.
Maja Zabel, Peter A Tauber, Winfried F Pickl.
Immunol Lett, 2019 Jun 11; 212. PMID: 31181279    Free PMC article.
Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.
Taylor T Chrisikos, Yifan Zhou, +3 authors, Haiyan S Li.
Mol Immunol, 2018 Mar 20; 110. PMID: 29549977    Free PMC article.
Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
Andrew J Rech, Hannah Dada, +4 authors, Robert H Vonderheide.
Cancer Res, 2018 May 31; 78(15). PMID: 29844122    Free PMC article.
An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
Yoon Se Lee, Daniel E Johnson, Jennifer R Grandis.
Expert Opin Emerg Drugs, 2018 Nov 01; 23(4). PMID: 30376740    Free PMC article.
Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies.
Xue Han, Matthew D Vesely.
Int Rev Cell Mol Biol, 2019 Jan 13; 342. PMID: 30635089    Free PMC article.
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
Hayley S Ma, Bibhav Poudel, +9 authors, Elizabeth M Jaffee.
Cancer Immunol Res, 2019 Jan 16; 7(3). PMID: 30642833    Free PMC article.
Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
Xiaobo Liu, Yingjie Zhao, +8 authors, Fubin Li.
Nat Commun, 2019 Sep 29; 10(1). PMID: 31562320    Free PMC article.
Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory.
Wenhao Luo, Gang Yang, +8 authors, Taiping Zhang.
Cancer Cell Int, 2020 Mar 12; 20. PMID: 32158356    Free PMC article.
Concepts for agonistic targeting of CD40 in immuno-oncology.
David M Richards, Julian P Sefrin, +2 authors, Christian Merz.
Hum Vaccin Immunother, 2019 Aug 14; 16(2). PMID: 31403344    Free PMC article.
Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy.
Maria Georganaki, Mohanraj Ramachandran, +15 authors, Anna Dimberg.
Oncoimmunology, 2020 Apr 02; 9(1). PMID: 32231867    Free PMC article.
Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect.
Nathan Suek, Luis Felipe Campesato, Taha Merghoub, Danny N Khalil.
Front Immunol, 2019 Apr 20; 10. PMID: 31001249    Free PMC article.
Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting.
Alexey V Baldin, Lyudmila V Savvateeva, Alexandr V Bazhin, Andrey A Zamyatnin.
Cancers (Basel), 2020 Mar 11; 12(3). PMID: 32150821    Free PMC article.
Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy.
Katherine M Audsley, Alison M McDonnell, Jason Waithman.
Cells, 2020 Mar 04; 9(3). PMID: 32121071    Free PMC article.
Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer.
Ann Hanna, Brandon J Metge, +5 authors, Lalita A Shevde.
Oncoimmunology, 2019 Feb 07; 8(3). PMID: 30723576    Free PMC article.
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Alexander H Morrison, Mark S Diamond, +2 authors, Robert H Vonderheide.
Proc Natl Acad Sci U S A, 2020 Mar 28; 117(14). PMID: 32213589    Free PMC article.
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Christina Claus, Claudia Ferrara, +54 authors, Pablo Umaña.
Sci Transl Med, 2019 Jun 14; 11(496). PMID: 31189721    Free PMC article.
Highly Cited.
Targeting Antigens to CD180 but Not CD40 Programs Immature and Mature B Cell Subsets to Become Efficient APCs.
Kelsey Roe, Geraldine L Shu, +3 authors, Edward A Clark.
J Immunol, 2019 Sep 06; 203(7). PMID: 31484732    Free PMC article.
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice.
Simone Ragusa, Borja Prat-Luri, +17 authors, Tatiana V Petrova.
J Clin Invest, 2020 Feb 06; 130(3). PMID: 32015230    Free PMC article.
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Xiaojie Yu, H T Claude Chan, +13 authors, Mark S Cragg.
Cancer Cell, 2020 May 23; 37(6). PMID: 32442402    Free PMC article.
CD40 agonist-induced IL-12p40 potentiates hepatotoxicity.
Caroline Bonnans, Graham Thomas, +10 authors, Yan Qu.
J Immunother Cancer, 2020 Jun 01; 8(1). PMID: 32474414    Free PMC article.
Novel Targets for the Treatment of Melanoma.
Lara Ambrosi, Shaheer Khan, Richard D Carvajal, Jessica Yang.
Curr Oncol Rep, 2019 Nov 07; 21(11). PMID: 31696329
Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations.
Todd A Aguilera, Eslam A Elghonaimy, +10 authors, Amato J Giaccia.
Clin Cancer Res, 2020 Feb 27; 26(12). PMID: 32098769    Free PMC article.
Line-selective macrophage activation with an anti-CD40 antibody drives a hemophagocytic syndrome in mice.
Giada Ingoglia, Ayla Yalamanoglu, +8 authors, Florence Vallelian.
Blood Adv, 2020 Jun 20; 4(12). PMID: 32559293    Free PMC article.
Brain immunology and immunotherapy in brain tumours.
John H Sampson, Michael D Gunn, Peter E Fecci, David M Ashley.
Nat Rev Cancer, 2019 Dec 07; 20(1). PMID: 31806885    Free PMC article.
Identification of Potential Key Genes and Pathways for Inflammatory Breast Cancer Based on GEO and TCGA Databases.
Qing Lv, Yansong Liu, +3 authors, Dong Meng.
Onco Targets Ther, 2020 Jul 02; 13. PMID: 32606769    Free PMC article.
CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells.
Rebeca Arroyo Hornero, Christos Georgiadis, +8 authors, Joanna Hester.
Commun Biol, 2020 Jul 16; 3(1). PMID: 32665635    Free PMC article.
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
Sai Ping Lau, Nadine van Montfoort, +18 authors, Casper H J van Eijck.
J Immunother Cancer, 2020 Jul 22; 8(2). PMID: 32690771    Free PMC article.
Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer Immunotherapy.
Peter D Koch, Christopher B Rodell, +2 authors, Ralph Weissleder.
Cell Chem Biol, 2020 Jan 07; 27(1). PMID: 31902676    Free PMC article.
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy.
Lukas Amon, Lukas Hatscher, +2 authors, Christian H K Lehmann.
Pharmaceutics, 2020 Jul 18; 12(7). PMID: 32674488    Free PMC article.
Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity.
Natasha D Sheybani, Alexandra R Witter, +3 authors, Richard J Price.
J Immunother Cancer, 2020 Aug 21; 8(2). PMID: 32819975    Free PMC article.
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities.
Kate Young, Daniel J Hughes, David Cunningham, Naureen Starling.
Ther Adv Med Oncol, 2018 Dec 24; 10. PMID: 30574212    Free PMC article.
Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment.
Robert A Belderbos, Joachim G J V Aerts, Heleen Vroman.
Mol Ther Oncolytics, 2019 Apr 26; 13. PMID: 31020037    Free PMC article.
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.
Sebastian Chrétien, Ioannis Zerdes, +2 authors, Theodoros Foukakis.
Cancers (Basel), 2019 May 08; 11(5). PMID: 31060337    Free PMC article.
A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects in vitro and in vivo.
Valeria Governa, Alvaro Brittoli, +7 authors, Emanuele Trella.
Oncoimmunology, 2019 May 10; 8(5). PMID: 31069131    Free PMC article.
The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40.
Veronika Caisova, Liping Li, +14 authors, Karel Pacak.
Cancers (Basel), 2019 May 15; 11(5). PMID: 31083581    Free PMC article.
Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations.
Ruth J Davis, Robert L Ferris, Nicole C Schmitt.
Cancers Head Neck, 2016 Oct 01; 1. PMID: 31093342    Free PMC article.
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
Jean-Pascal Machiels, Carlos Gomez-Roca, +21 authors, Philippe Cassier.
J Immunother Cancer, 2020 Oct 25; 8(2). PMID: 33097612    Free PMC article.
Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations.
Madyson Colton, Eleanor J Cheadle, Jamie Honeychurch, Tim M Illidge.
Radiat Oncol, 2020 Nov 06; 15(1). PMID: 33148287    Free PMC article.
Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists.
Dana A Emerson, William L Redmond.
BioDrugs, 2018 Apr 11; 32(3). PMID: 29637478    Free PMC article.
Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
Celia Jacoberger-Foissac, Stephen J Blake, +5 authors, Michele Wl Teng.
J Immunother Cancer, 2020 Nov 18; 8(2). PMID: 33199513    Free PMC article.
Checkpoint immunotherapy in head and neck cancers.
Paul Zolkind, Ravindra Uppaluri.
Cancer Metastasis Rev, 2017 Aug 25; 36(3). PMID: 28836124    Free PMC article.
Immunotherapy Targeting Tumor-Associated Macrophages.
Yafei Liu, Rongsi Wang.
Front Med (Lausanne), 2020 Dec 01; 7. PMID: 33251232    Free PMC article.
Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.
Tim F Greten, Xin W Wang, Firouzeh Korangy.
Gut, 2015 Feb 11; 64(5). PMID: 25666193    Free PMC article.
Highly Cited. Review.
Emerging immunotherapies for bladder cancer.
Joseph W Kim, Yusuke Tomita, Jane Trepel, Andrea B Apolo.
Curr Opin Oncol, 2015 Mar 27; 27(3). PMID: 25811346    Free PMC article.
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
Hanley N Abramson.
Int J Mol Sci, 2018 Dec 14; 19(12). PMID: 30544512    Free PMC article.
Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
Chin-King Looi, Felicia Fei-Lei Chung, +3 authors, Chun-Wai Mai.
J Exp Clin Cancer Res, 2019 Apr 17; 38(1). PMID: 30987642    Free PMC article.
Highly Cited. Review.
Advances in engineering local drug delivery systems for cancer immunotherapy.
Peter Abdou, Zejun Wang, +4 authors, Zhen Gu.
Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2020 Apr 08; 12(5). PMID: 32255276    Free PMC article.
Designed proteins assemble antibodies into modular nanocages.
Robby Divine, Ha V Dang, +27 authors, David Baker.
bioRxiv, 2020 Dec 11;. PMID: 33299994    Free PMC article.
Targeting co-stimulatory molecules in autoimmune disease.
Natalie M Edner, Gianluca Carlesso, James S Rush, Lucy S K Walker.
Nat Rev Drug Discov, 2020 Sep 18; 19(12). PMID: 32939077
Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system.
Xiaohui Wang, Zhiqiang Wu, +3 authors, Weidong Han.
Front Med, 2020 Aug 15; 14(6). PMID: 32794014
Immune-Checkpoint Inhibitors in B-Cell Lymphoma.
Marc Armengol, Juliana Carvalho Santos, +3 authors, Gaël Roué.
Cancers (Basel), 2021 Jan 13; 13(2). PMID: 33430146    Free PMC article.
Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR.
Marta Compte, Seandean L Harwood, +9 authors, Luis Alvarez-Vallina.
Front Immunol, 2021 Jan 26; 11. PMID: 33488625    Free PMC article.
Next-Generation Immunotherapies to Improve Anticancer Immunity.
Yaoyao Shi, Katarzyna Tomczak, +3 authors, Cara Haymaker.
Front Pharmacol, 2021 Jan 29; 11. PMID: 33505304    Free PMC article.
Immunotherapy in Colorectal Cancer: Current and Future Strategies.
Akira Ooki, Eiji Shinozaki, Kensei Yamaguchi.
J Anus Rectum Colon, 2021 Feb 05; 5(1). PMID: 33537496    Free PMC article.
A Hepatitis B Virus-Derived Peptide Exerts an Anticancer Effect via TNF/iNOS-producing Dendritic Cells in Tumor-Bearing Mouse Model.
Soo-Bin Yang, Mi-Hyun Lee, +2 authors, Bum-Joon Kim.
Cancers (Basel), 2021 Jan 28; 13(3). PMID: 33499256    Free PMC article.
Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA).
Rogelio Medina, Herui Wang, +15 authors, Zhengping Zhuang.
Adv Ther (Weinh), 2021 Mar 13; 3(9). PMID: 33709018    Free PMC article.
Combination therapies utilizing neoepitope-targeted vaccines.
Karin L Lee, Jeffrey Schlom, Duane H Hamilton.
Cancer Immunol Immunother, 2020 Oct 10; 70(4). PMID: 33033852    Free PMC article.
Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
Vassilis Genoud, Denis Migliorini.
Int J Mol Sci, 2021 Apr 04; 22(7). PMID: 33800593    Free PMC article.
Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma.
Pashayar P Lookian, David Zhao, +5 authors, Zhengping Zhuang.
Int J Mol Sci, 2021 Apr 04; 22(7). PMID: 33810617    Free PMC article.
IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma.
Shubhra Singh, Zhilan Xiao, +10 authors, Manisha Singh.
J Immunol, 2021 Mar 17; 206(8). PMID: 33722878    Free PMC article.
Cancer Vaccines, Adjuvants, and Delivery Systems.
Samantha J Paston, Victoria A Brentville, Peter Symonds, Lindy G Durrant.
Front Immunol, 2021 Apr 17; 12. PMID: 33859638    Free PMC article.
The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies.
Marwa Elsayed, Maen Abdelrahim.
Biomedicines, 2021 May 01; 9(4). PMID: 33917380    Free PMC article.
Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy.
Tiziana Cotechini, Aline Atallah, Arielle Grossman.
Cells, 2021 May 01; 10(4). PMID: 33924237    Free PMC article.
Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.
Xingzhou Peng, Junjie Wang, +2 authors, Zhihong Zhang.
Cell Mol Life Sci, 2021 May 09; 78(12). PMID: 33963442
Immunotherapies targeting stimulatory pathways and beyond.
Julian A Marin-Acevedo, ErinMarie O Kimbrough, +2 authors, Yanyan Lou.
J Hematol Oncol, 2021 May 14; 14(1). PMID: 33980266    Free PMC article.
Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy.
Benjamin Wolfson, S Elizabeth Franks, James W Hodge.
Vaccines (Basel), 2021 Jun 03; 9(5). PMID: 34063388    Free PMC article.
Sequential Treatment of Bioresponsive Nanoparticles Elicits Antiangiogenesis and Apoptosis and Synergizes with a CD40 Agonist for Antitumor Immunity.
Xiang Ling, Xiaomin Jiang, +4 authors, Wenbin Lin.
ACS Nano, 2020 Dec 22; 15(1). PMID: 33347262    Free PMC article.
VISTA is an activating receptor in human monocytes.
Bryan M Rogers, Laura Smith, +14 authors, Gabriel R Starbeck-Miller.
J Exp Med, 2021 Jun 10; 218(8). PMID: 34106206    Free PMC article.
C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
Kosuke Sasaki, Shigetsugu Takano, +6 authors, Masayuki Ohtsuka.
J Exp Clin Cancer Res, 2021 Jun 26; 40(1). PMID: 34167573    Free PMC article.
Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.
Raquel Delgado, Karoline Kielbassa, +5 authors, Eric Eldering.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34205588    Free PMC article.
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies.
Timothy N J Bullock.
Cell Mol Immunol, 2021 Jul 21; 19(1). PMID: 34282297    Free PMC article.
Cellular based immunotherapy for primary liver cancer.
Yuanyuan Zheng, Yan Li, +8 authors, Chuanyong Guo.
J Exp Clin Cancer Res, 2021 Aug 11; 40(1). PMID: 34372912    Free PMC article.
Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy.
Ondrej Uher, Thanh-Truc Huynh, +10 authors, Karel Pacak.
Cancers (Basel), 2021 Aug 28; 13(16). PMID: 34439097    Free PMC article.
Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain.
Simone Camelliti, Valentino Le Noci, +12 authors, Michele Sommariva.
Cancers (Basel), 2021 Aug 28; 13(16). PMID: 34439233    Free PMC article.
CD40 Agonist Monoclonal Antibody-Mediated Hepatitis in TNF-Receptor 1 Gene Knockout Mice.
Oksana Raabe, Thomas Birchler, Hubert Rehrauer, Elisabeth Eppler.
Biomedicines, 2021 Aug 28; 9(8). PMID: 34440067    Free PMC article.
A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy.
Jie Liang, Huihui Zhang, +7 authors, Xuanming Yang.
Cancer Manag Res, 2021 Sep 16; 13. PMID: 34522140    Free PMC article.
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Vassilis Genoud, Felipe I Espinoza, +6 authors, Paul R Walker.
JCI Insight, 2021 Aug 18; 6(18). PMID: 34403371    Free PMC article.
Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect.
Mohammad Heiat, Hamid Hashemi Yeganeh, Seyed Moayed Alavian, Ehsan Rezaie.
Toxins (Basel), 2021 Oct 23; 13(10). PMID: 34679012    Free PMC article.
Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
Hsuan-Chen Liu, Dixita I Viswanath, +16 authors, Alessandro Grattoni.
Int J Radiat Oncol Biol Phys, 2020 Aug 10; 110(2). PMID: 32768562    Free PMC article.
Designed proteins assemble antibodies into modular nanocages.
Robby Divine, Ha V Dang, +27 authors, David Baker.
Science, 2021 Apr 03; 372(6537). PMID: 33795432    Free PMC article.
Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives.
Marije J Voskamp, Shuang Li, +3 authors, Niels Bovenschen.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771550    Free PMC article.
Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy.
Luis Felipe Olguín-Contreras, Anna N Mendler, +2 authors, Elfriede Noessner.
Front Immunol, 2021 Dec 17; 12. PMID: 34912334    Free PMC article.
Immune System in Action.
Bettzy Stephen, Joud Hajjar.
Adv Exp Med Biol, 2022 Jan 02; 1342. PMID: 34972961
Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Valentina Ceglia, Sandra Zurawski, +7 authors, Gerard Zurawski.
Front Immunol, 2022 Feb 01; 12. PMID: 35095862    Free PMC article.
LncRNA PCGEM1 in Human Cancers: Functions, Mechanisms and Promising Clinical Utility.
Yuanshuai Su, Xinyu Gu, +3 authors, Lanjuan Li.
Front Oncol, 2022 Mar 11; 12. PMID: 35265529    Free PMC article.
The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation.
Eva Sum, Moritz Rapp, +4 authors, Pablo Umaña.
J Immunother Cancer, 2022 Mar 17; 10(3). PMID: 35292514    Free PMC article.